Colon cancer chemoprevention with ginseng and other botanicals. by Wargovich, M J
INTRODUCTION
Colorectal cancer is still a leading cause of cancer deaths
in the United States and is increasing at an alarming rate in
Asia (1, 2). Cancer chemoprevention is a discipline of cancer
research emerging from its infancy 20 yr ago to now gain
center stage in the armamentarium against cancer (3). Yet it
has not abandoned its founding principles of discovery of
natural and man-made agents that inhibit the initiation,
promotion, or progression of cancer. The pioneering efforts
of Wattenberg (4, 5) first focused the search for chemopre-
ventive agents by examining the diet for them. Dietary pat-
terns may account for wide differences in the risk for lead-
ing cancers across the world. It was logical to propose that
dietary factors, in countries with populations at low risk for
certain cancers could be identified and exploited for use in
man as cancer inhibitors (6). From the origins of this disci-
pline it was found that compounds in cruciferous vegetables,
alliums, citrus, soy, and tea had the ability to inhibit experi-
mentally-induced cancers in animal models (7). In the early
1980s the National Cancer Institute (U.S.A.) established
within its structure a chemoprevention screening program
to identify promising agents for rapid development into
clinical trial agents. This program encompassed a tier of
strategies to first select candidate agents, evaluate these agents
in in vitro based test systems (often involving human tumor
cell lines), then test the most promising agents in short-term
animal models for chemoprevention efficacy (8). Finally, the
program attempted to confirm the anti-tumor or cancer pre-
ventive aspects of these agents in long-term tumor studies
in mice and rats. The animal models employed are designed
to test the same agents across tumor type, and these were
targeted to the most common cancers: lung, breast, colon
and prostate. During this effort a list of hundreds of poten-
tial compounds were distilled down to a dozen or so per year
with the remaining goal of progressing them to clinical tri-
als (9). As a discipline we are finally at the point in cancer
chemoprevention where we are able to see the fruits of this
long process, as studies in high risk individuals for cancer
have begun. As a laboratory associated with this effort we
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Colon Cancer Chemoprevention With Ginseng and Other Botanicals
Colorectal cancer is becoming increasingly common in Asian countries and still
remains the second leading cause of cancer deaths in the United States.
Efforts to prevent colon cancer have targeted early detection through screening
and chemoprevention. For the last ten years our laboratory has utilized an in
vivo screening assay for the testing of potential cancer preventives for colon
cancer. We have conducted investigations on over 150 compounds including
many with botanical or herbal origins. As part of our program on natural pro-
ducts we have examined a number of herbal and botanical products in the aber-
rant crypt foci (ACF) assay including Korean red ginseng powder, green tea cat-
echins, curcumin from the Indian culinary spice, tumeric, compounds from garlic
and onion, resveratrol from red grapes, among others. In the ginseng experi-
ments  groups of 10 F344 rats were fed ginseng powder at a dose of 0.5 g/kg or
2 mg/kg for 5 weeks. During weeks 2 and 3 rats were injected with 10 mg/kg
azoxymethane to induce ACF. Controls (n=10) did not receive azoxymethane
(AOM). Rats were killed by CO2 overdose and ACF counted in the rat colon. In
8 week post-initiation experiments ginseng powder inhibited the progression of
established ACF, indicating a cytostatic effect. This may be due to an anti-
inflammatory effect.  There is a body of literature that suggests that compounds
in wine, tumeric, and tea inhibit cyclooxygenases, thus reducing prostaglandin-
mediated effects on the colon. As colon tumors have been shown to highly
express COX-2 protein, and given, that many NSAID drugs also suppress COX-
1, it is tempting to speculate that herbal products that inhibit one or both forms of
the COX enzyme will be effective agents for the prevention of cancer in man.
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have evaluated over 150 potential agents for the chemopre-
vention of colon cancer (10-12). While many of these in-
cluded drugs created for other medical purposes, we also
investigated a number of naturally occurring agents. Cur-
rently, the laboratory has focused on herbal and botanical
sources of chemopreventive agents because of the increasing
use of complementary and alternative medicines among
cancer patients and the general public (13). The primary
assay for efficacy screening is the aberrant crypt assay in the
rat colon.
CHEMOPREVENTION EFFICACY STUDIES IN
ANIMAL MODELS FOR COLON CANCER
The most widely used animal model sytem for the evalu-
ation of chemopreventive activity has been azoxymethane-
induced (AOM) colon cancer in the Sprague-Dawley or F344
rat, although more recent efforts have employed the APCmin+/-
mouse (14, 15). The AOM model is widely appreciated for
its histological similarity to human colon cancer, although
tumorigenesis assays can take up to a year to complete. Many
of the same molecular and biochemical defects in human
cancer are also observed in the AOM model, although some
differences in the role of tumor suppressor genes such as p53
are notable (16). For this reason, many investigators have
turned to intermediate biomarkers that economize in terms
of duration of the experiment. An ideal compromise in the
AOM model is the aberrant crypt foci (ACF) assay.
Aberrant crypt foci are precursor lesions for colon cancer
(17). Arising out of the normal colonic epithelium they are
dilated, often protruding above the surface of neighboring
normal crypts. This protrusion is a  “signature”for ACFs
and they are easily detected in carcinogen-treated rodent
colon by immersing the tissue briefly in a solution of methy-
lene blue and viewing the tissue under a dissecting micro-
scope (Fig. 1). ACFs show many abnormal features histo-
logically. They are wider then normal crypts and exhibit a
slit-like opening when viewed from above compared to the
circular appearance of normal crypts (18, 19). They often
are hyperplastic although dysplasia is also common. ACFs
are more proliferative than normal cryptal glands and are
more mitotic. At the molecular level ACFs often are mutated
in the apc gene and have a mutated ras oncogene, although
these are more likely to occur in the more dysplastic ACFs
(20-22). Defects in cell adhesion molecules have been found
(23, 24). While ACFs are considered to be precursors to ade-
nomas, and are found in humans at risk for colon cancer, not
all ACFs become adenomas, just as only a few adenomas
become colon cancers (25). Still, as a proxy for colon cancer,
ACFs have been extensively used as an intermediate biomark-
er for colon cancer prevention research.
ACFs are induced in rodents by all known carcinogens,
thus making them an attractive model for chemopreven-
tion. In our laboratory we have developed two protocols for
the evaluation of potential chemopreventive agents. In the
first protocol, F344 rats are injected twice at 15 mg/kg with
AOM during the first two weeks of a five week experimen-
tal period. The test compound is fed in the diet during the
four week period (2 weeks following the last injection of
AOM). This protocol evaluates the effects of the test com-
pound during the initiation phase, when interactions with
the carcinogen’ s metabolism can occur. In the second proto-
col we repeat the same course of treatment but do not expose
the animals to the test compounds until ACFs have grown
in the rat colon for 4 weeks. During a second four week peri-
od we introduce the test agent, thus evaluating the effects of
the agent on outgrowth and progression of ACFs. This fea-
Fig. 1. Aberrant crypt foci in methylene blue stained colon. Note
large multicrypt cluster in ACF (× 50). Fig. 2. Experimental design for chemoprevention studies.
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ture allows the more facile testing of an agent on the out-
growth of multicrypt-ACFs which are more likely to acquire
subsequent mutations and progress to cancer. The protocols
we have used are shown in Fig. 2. As described above, we
have tested a significant number of compounds in this assay
and chemical class/activity patterns have begun to emerge.
Recently we have engaged the hypothesis that botanical and
herbal supplements may indeed be sources of cancer chemo-
preventive agents. To illustrate one series of investigations
we have recently tested Korean red ginseng for chemopre-
ventive activity in the ACF assay.
EVALUATION OF KOREAN RED GINSENG FOR
CHEMOPREVENTION OF COLON CANCER
A wealth of evidence links elements of the Asian diet to
reduced risk for certain cancers, hence the recent interest in
herbals and botanicals of Asian origin as potential sources of
cancer inhibitors (26-28). Korean red ginseng (Panax ginseng
C.A. Meyer cultivated in Korea) is valued for its human-
shaped storage root that has a long history of purported
medicinal uses. Ginseng has been widely reported to be an
effective tonic or has adaptogenic activity which effectively
increases the ability to withstand stressors (26, 29, 30). Many
other medical effects are attributed to ginseng use, mainly
associated with increased energy levels and feelings of well-
being.
The major agents in ginseng root thought to be responsi-
ble for medicinal activity are the triterpene saponins, also
known as ginsenosides, and many of these appear in extracts
of red ginseng (31-33). Red ginseng has been tested for anti-
carcinogenicity in a variety of tumor models. Yun et al. (34)
found that aged red ginseng powder was more effective
than fresh ginseng powder in reducing benzo(a)pyrene
induced lung adenoma in mice. Inhibition was also found
for lung tumors induced by dimethylbenz(a)anthracene in
mice (33). While over 30 ginsenosides have now been iden-
tified in ginseng only a few have been isolated and tested
for cancer preventive effects.
To confirm the effect of Korean red ginseng on experi-
mentally induced colon cancer we tested a spray dried extract
powder in the ACF assay. The experimental design is shown
in Fig. 2. Forty male F344 male rats (Harlan Sprague Daw-
ley) were randomized into 4 treatment groups of 10 rats
each for protocol A and B. Group 1 did not receive ginseng.
Group 2 received red ginseng powder dissolved in tap water
to a concentration of 0.5 mg/kg body weight whereas Groups
3 and 4 received ginseng at a concentration of 2 mg/kg body
weight. Groups 1-3 were injected with azoxymethane (Sigma)
at a concentration of  15 mg/kg at weeks 2 and 3 of the ex-
periments. Protocol A tested the effects of red ginseng dur-
ing weeks 2-5, whereas the ginseng was given only during
weeks 4-8 in protocol B. All animals were fed the AIN93G
semi-purified diet (Dyets) throughout the experimental
periods. At the end of 5 weeks (Protocol A) or 8 weeks (pro-
tocol B) the rats were killed by CO2 overdose. Their colons
were removed, flushed free with PBS, then stained briefly in
0.3% methylene blue. The colons were fixed flatly in buffered
formalin for 24 hr, then viewed under a dissecting micro-
scope for the evaluation of ACF. Only dysplastic ACFs were
scored. Both hyperplastic and dysplastic ACFs were present
in the rat colons.
The results of these experiments are shown in Fig. 3 and
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Fig. 4. Effect of Korean red ginseng on induction of ACF by
azoxymethane in the rat colon during the post-initiation phase of
carcinogenesis. Data significantly different from AOM only group
at p<.05 indicated by*.
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Fig. 3. Effect of Korean red ginseng on induction of ACF by
azoxymethane in the rat colon during initiation of carcinogenesis.
Data significantly different from AOM only group at p<.05 indicat-
ed by*.
*
*
*
Dysplastic Crypts per ACF
Protocol A
AOM ONLY
0.5 mg/kg GINSENG
2 mg/kg GINSENGS84 M.J. Wargovich
4. When red ginseng powder was delivered during the ini-
tiation phase of carcinogenesis, that is, during the same time
with exposure to AOM only a modest inhibition of ACF was
noted and only at the 0.5 mg/kg dose of ginseng. Thus, the
effect of ginseng during the initiation of ACFs from the
normal mucosa is relatively weak. However, after ACFs have
been established in the colon during a four week outgrowth
period, an additional four week exposure to red ginseng at a
dose of 2 mg/kg significantly reduced the incidence of ACFs.
We also noted that the ginseng powder during the post-ini-
tiation time limited the number of multiple crypt contain-
ing foci.
These results suggest that some factors in red ginseng
powder are inhibitory toward the growth of preneoplastic
lesions in the rat colon treated with azoxymethane. The
mechanisms by which this occurred are currently unknown
but at least two possibilities may explain the effect. Ginseng
has been shown to inhibit the proliferation of a number of
tumor cells in culture and could exert a general antiprolifer-
ative effect on the colonic epithelium (35, 36). The second
possibility is that ginseng could, through inhibition of anti-
inflammatory pathways preferentially inhibit the growth of
ACFs. Previous work in our laboratory has established that
non-steroidal anti-inflammatory drugs such as aspirin, ibupro-
fen, and indomethacin are potent suppressors of colon car-
cinogenesis and ACFs. It is tempting to speculate that spe-
cific ginsenosides might inhibit either COX-1 or COX-2 as
inhibition of either of these isoforms results in chemopre-
vention of colon cancer (37-39). COX-2 is specifically ele-
vated in colon tumors and at least some COX-2 selective
drugs are chemopreventive in the AOM model (40). These
results also verify the report of Li et al. (41) who examined
the effect of ginseng on 1, 2 dimethylhyrazine-induced ACF
in the rat colon, however, their study did not detect an chemo-
preventive effect of ginseng in the post-initiation phase of
carcinogenesis. Dimethylhydrazine is the metabolic precursor
to AOM used in the present study and it cannot be ruled out
that ginseng may affect carcinogen metabolism. In any case,
it is clear that extended studies should be performed to fur-
ther confirm the chemopreventive activity of red ginseng
powder on ACFs and colon tumors.
CHEMOPREVENTION OF COLON CANCER BY
OTHER BOTANICALS
As part of a research program focused on the identification
of naturally occurring inhibitors of cancer our laboratory has
also investigated a number of botanicals with chemopreven-
tive activity. Substances that were active either in protocol
A or B include: epigallocatechin gallate from green tea, cur-
cumin from the spice turmeric, several compounds from
garlic (s-allyl cysteine, diallyl sulfide), quercetin from onions,
and indole 3 carbinol from cruciferous vegetables, all elements
found in traditional Asian diets (11, 12, 42). The very promising
potency of non-steroidal anti-inflammatory drugs (NSAIDs)
yields the prospect of searching for botanical sources of anti-
inflammatories (43-45). As alluded to earlier, most NSAIDs
have been shown to inhibit ACF formation and colon cancer
in the AOM model, but widespread use of NSAIDs is lim-
ited by their most common and significant side effect: ulcer-
ation with intestinal bleeding. One of the primary screens
for biological activity when new ethnopharmacological com-
pounds are discovered is for anti-inflammatory activity in the
paw edema assay. Literally scores of plants have anti-inflam-
matory effects and the results are in the ethnopharmacological
literature. Among those we are interested in testing include
between ginger, tumeric, cat’ s claw, gingko, and grapeseed
and we are in the process of comparing their effects with the
common NSAIDs that we have shown to be preventive in
the rat model.
SUMMARY
The field of cancer chemoprevention has found fertile
ground in its applicability of colon cancer and other neoplas-
tic diseases. Factors in the Asian diet such as tea, spices, and
medicinal herbs are now being screened for potential use as
cancer chemopreventives in man. There is interest in sys-
tematically testing ancient medicinal herbs for this activity. 
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